OGN vs. ABT

In the year-to-date period, OGN achieves a -16.73% return, which is significantly lower than ABT's 15.04% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Organon & Co. (OGN) and Abbott Laboratories (ABT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current OGN Sharpe Ratio is -0.72, which is lower than the ABT Sharpe Ratio of 1.08. The chart below compares the historical Sharpe Ratios of OGN and ABT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

OGN's dividend yield for the trailing twelve months is around 9.18%, more than ABT's 1.77% yield.

The maximum OGN drawdown since its inception was -69.56%, which is greater than ABT's maximum drawdown of -45.66%. Use the drawdown chart below to compare losses from any high point for OGN and ABT. For additional features, visit the drawdowns tool.

Organon & Co. (OGN) has a higher volatility of 22.63% compared to Abbott Laboratories (ABT) at 8.98%. This indicates that OGN's price experiences larger fluctuations and is considered to be riskier than ABT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Organon & Co. and Abbott Laboratories. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.